Little is known about the significance of hospitals as point sources for the emission of organic micropollutants into the aquatic environment. A mass flow analysis of pharmaceuticals and diagnostics used in hospitals was performed on the site of a representative Swiss cantonal hospital. Specifically, the consumption of iodinated X-ray contrast media (ICM) and cytostatics in the corresponding medical applications, radiology and oncology, and their discharge into hospital wastewater and afterwards the municipal wastewater treatment plant were analyzed. Emission levels within one day and over several days were found to correlate with the pharmacokinetic excretion pattern and the consumed amounts in the hospital during these days. ICM total emissions vary substantially from day to day from 255 to 1'259 g/d, with a maximum on the day when emissions of 8-10 mg/d. 1.1%, 1.4% and 3.7% of the total excreted amounts of the cytostatics 5-fluorouracil, gemcitabine and 2',2'-difluorodeoxyuridine (the main metabolite of gemcitabine), respectively, were found in the hospital wastewater, whereas 49% of the ICM sum was detected, showing a high variability among compounds. These recoveries can essentially be explained by the high amount administered to out-patients (70% for cytostatics, 50% for ICM), therefore only part of this dose is expected to be excreted on-site. In addition, this study points out critical issues to consider when sampling in hospital sewer systems. Flow proportional sampling over a longer period is crucial to compute robust hospital mass flows.
Introduction
Hospitals are sources for pharmaceuticals and disinfectants, and can be seen, besides households and industries, as hotspots for the discharge of these emerging contaminants into the sewer network. If not degraded in the municipal wastewater treatment plants (WWTP), they reach surface waters, with potential impact on the ecosystem and human health (1,2). Within the top 100 active compounds list of the Swiss national sales data of pharmaceuticals, 18 % of the medicaments' total volume is being administered in hospitals (3).
The occurrence of specific iodinated X-ray contrast media (ICM) (4,5), anti-tumor agents (6-8), carbamazepine, diclofenac and metamizole (9,10), as well as antibiotics (11,12) in hospital effluents have been reported. ICM (13) and cytostatics (14) are administered mainly in hospitals and therefore high amounts are expected in the hospital sewer. ICM are 100% dispensed in radiology applications and the consumption of the cytostatic cyclophosphamide in hospital amounts to 70% of its total consumption. The occurrence and fate of cyclophosphamide and ifosfamide were studied in WWTPs and surface waters in Switzerland, and were found in concentrations from ≤ 50 to 170 pg/L in surface water (15) . Due to a lack of studies on chronic effects on aquatic organisms, a final risk assessment cannot be made. Being intentionally designed to inhibit DNA synthesis, damage the DNA as well as being themselves carcinogenic and teratogenic, potential of cytostatics for causing adverse environmental effects is high, although still not proved (16) . 5-fluorouracil was discovered as one of the most toxic and also highly used cytostatic compound by Zounkova et al. (17) . ICM are not toxicologically relevant, but in general highly persistent polar compounds, measured in groundwater up to 2.4 μg/l for iopamidol (18) . Due to the high administration of ICM and cytostatics in hospitals, these institutions are presumed to be one of the major point sources for emission in hospital wastewater and contamination of the aquatic environment. In Switzerland as in the majority of other countries, hospital wastewater is not treated separately (except for radioactive compounds), and is released into the public sewer system together with domestic wastewater. As Pauwels and Verstraete (19) report, data are needed for the assessment of the potential impacts of hospital emissions of organic micropollutants and multiresistant microbial strains into the environment. The toxicity is considered to be 5-15 times higher in hospital wastewater then in domestic wastewater (20) .
This study aimed to perform a time resolved mass flow analysis of hospital drugs -six ICM: iopamidol, iomeprol, iopromide, iohexol, ioxitalamic acid and amidotrizoic acid (diatrizoate); two cytostatics: 5-fluorouracil, gemcitabine and one human metabolite of gemcitabine, 2',2'-difluorodeoxyuridine (dFdU) -analyzing their consumption in a representative hospital and their occurrence in the hospital wastewater. The chosen Cantonal Hospital belongs with 415 occupied beds to the 10 biggest Swiss hospitals. Volume-proportional sampling is done to be able to compare measured emissions with the actual consumption levels to come up with amounts of the analyzed drugs really excreted into the hospital sewer system, what has not been reported so far.
These results enable more refined modeling of real mass flows from hospitals and comparison to mass flows from domestic wastewater, what was reported for carbamazepine, diclofenac and metamizole (9,10). Such evaluations allow for predicting pollutant loads in surface waters, and for assessing the significance of hospital discharges on the surface waters quality.
Material and methods

Description of sites and sampling
Cantonal Hospital and sampling of its wastewater
The cantonal hospital has 415 occupied beds and produces a volume of 135'000 As hospital wastewater is highly contaminated and for certain pharmaceuticals and pathogens up to about 100 times more polluted than municipal WWTP influents, considerations of full personal and instrumental safety measures are recommended for the work with hospital effluents (22) . All instruments in contact with raw hospital wastewater were autoclaved or chemically disinfected when thermal sterilization was not applicable.
More details are given in the Supporting Information (S1).
Assessment of sampling uncertainty
To determine the expected sampling uncertainty (23), the following data are needed (Tab.S2, Supporting Information): information about the sewer network (e.g.
location of buffer tanks), distance from sanitary appliances to the sampling point, target medical departmental activities and number of toilet flushes, the administered dose and the number of toilet flushes related to the target active compounds.
For the average sampling interval of eight minutes the uncertainty was calculated assuming different numbers of toilet flushes per 18-hour period. In the case of only one or two toilet flushes, representing one patient being treated in the hospital but excreting a part also at home, a sampling uncertainty of -100 to +130% (68%-quantile) was estimated. For 18 toilet flushes (stemming from about 2-5 patients per day with 4.5 toilet flushes per patient) the sampling uncertainty is approximately ±50%, for 30 pulses (6-9 patients per day) the deviation is around ±40%, and for 50 pulses (10-12 patients per day) the deviation is in the order of ±30% (see also Tab.S8, Supporting Information).
Description of WWTP and sampling of its wastewater
The hospital wastewater is discharged to a WWTP which treats the wastewater of 115'000 inhabitants. 
Samples preparation and measurement
The analytical methods were adapted from Ternes et al. (24) for ICM and from Kovalova et al. (25) for cytostatics. More details on analytes, sample preparation and measurement are given in the Supporting Information (S3).
Quality assurance
Concentrations were calculated by using external calibration with standards in nanopure water and relating to the peak area of the internal standard. For ICM, a comparison with standard addition was done and the deviation to external calibration was for hospital wastewater 7(±9)%. The absolute extraction recovery of the internal standard DMI was 75-135%. Absolute recoveries (67-138% for ICM, 40-79% for cytostatics) and relative recoveries (65-129% for ICM, 54-118% for cytostatics) were calculated for each compound and wastewater matrix over the whole method (Tab.S5, Supporting Information). Results were not corrected by the relative recoveries, except for dFdU.
Limits of quantification (LOQ) for ICM range from 0.2-20 μg/l for hospital wastewater and from 0.01-0.3 μg/l for WWTP wastewater; LOQ for the cytostatics range between 0.9 -9 ng/L for hospital wastewater. Like ICM, mass flow profiles of cytostatics show high daily variations (Fig. 1) .
Pharmacokinetic information on the analytes
Well detectable levels of all three compounds were measured between 11:00-20:30. In the night fractions, no parent cytostatic compound was detected above LOQ, while the human metabolite dFdU was observed also during the night. The measured mass flow profile is in agreement with the pharmacokinetic knowledge. The oncology treatments are done during the day, and the major part of the parent compounds were expected to be emitted also during the day, after 1 h for 5-fluorouracil and within 6 h for gemcitabine.
The profile of gemcitabine presents the excretion pattern of one hospitalized patient -the only patient treated with this substance (2'300 mg) that day -staying overnight.
Assuming a morning treatment, he excretes the gemcitabine and its metabolite dFdU in a first (09:35-11:45) and second period (14:25-17:05), which is physiologically relevant.
The metabolite is excreted in higher amounts: ratios of dFdU / gemcitabine are 10 resp. 3 in the two periods, which are comparable to the expected ratio of 6-17 in the excreted urine within the first six hours after infusion (30). In the night samples, longer elimination half lives for the metabolite dFdU explain the presence of the metabolized form. (Fig.2) . Measureable concentrations were found when a treatment took place, and whenever gemcitabine is present, also dFdU was found. The highest load of 9.7 mg/d for gemcitabine (last sampling day) was found when also a relatively high daily consumption occurred. Such high variations of mass loads of cytostatics in hospital wastewater were also observed in an Austrian study (7) and are caused by the low number of patients receiving chemotherapy. In average over the 9 days sampling period, the amount of 5-fluorouracil detected corresponds to 1.1% of the excreted quantity; for gemcitabine 1.4% of excretion, and for its metabolite dFdU 3.7% of excretion (Tab.2). For the interpretation of these results one first has to consider that the excretion rate can vary from patient to patient (section 2.3).
Correlation between consumption data and emissions in hospital wastewater
A comparison can be done to the study performed by Mahnik et al. (7) at Vienna University Hospital. They sampled wastewater directly from the oncology in-patient ward fed exclusively by 3 toilets and 3 showers (used by 18 patients). The concentrations of 5-fluorouracil were as high as 124 μg/L and loads recovered were in line with calculated loads when considering an excretion rate of 2%. When using a 2% excretion rate (instead of the average rate of 10% used for our calculation, Tab. 2), 5.5% of the expected excreted amount of 5-fluorouracil is recovered in the hospital sewer.
The main reason for the relatively low recoveries lay in the fact that the oncology department provides a high amount of ambulatory treatments: for 5-fluorouracil, 63%
were out-patients and 67% of the total quantity is administered to out-patients; for gemcitabine, the percentages are slightly higher (80% resp. 76%). Therefore, only about 30% of the administered dose is estimated to be excreted on-site into the hospital sewer.
Another reason for the low recovered loads lays in the relatively high sampling uncertainty especially for cytostatics which occurred due to the sampling procedure (see section 2.1.2). Because only a few patients are contributing to the daily load, the chance that toilet pulses were missed is high and an uncertainty of up to 120-130% was calculated. This high sampling uncertainly is causing the large overall uncertainties Addressing an issue that became relevant in the last years, this study pilots mass flow considerations for two groups of relevant xenobiotics and contributes to the current knowledge base. It shows that hospitals are indeed a point source for ICM. 49% of the administered amount was recovered in the hospital sewer, the rest is most probably excreted into domestic wastewater carried home by the 50% of out-patients treated at the hospital. Cytostatics are also found in relatively high amounts in the hospital sewer, however, only between 1.1 and 5.5% are recovered in the sewer and about 70% is carried home by out-patients. Therefore, the total volume of drugs ending up in the hospital sewer is smaller then the administered volume, accounting to 18% of the medicaments' total volume, and will further decrease when out-patient treatment is increasing as predicted for the future. Moreover, insight in the complexity of describing the hospital consumption and the excretion dynamics are given. An adequate sampling procedure was found to be crucial for mass flow analysis due to high input fluctuations. When continuous, flow-proportional sampling is not possible (e.g. as done in other studies (7,9)), a method is described on how to calculate optimal sampling intervals (fractions every 0.5-1 minute in our case) and sampling uncertainties. Sampling periods over several weeks are preferable. The obtained results on mass flows can be used as basis for models to predict concentrations of analytes in the surface water system. 
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